Pharmaxis Ltd (AU:SNT) has released an update.
Pharmaxis Ltd reports a significant stride in its clinical trial programs following the divestiture of its mannitol business unit, achieving $14 million in annual savings and advancing trial recruitment ahead of schedule. The company’s lead drug, SNT-5505, is making promising progress in a Phase 2 study for myelofibrosis, with 50% of recruitment completed and a government grant secured for a new study in Myelodysplastic Syndrome. These developments contribute to a potentially stronger commercial outlook for the drug and the company as a whole.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
